Results 51 to 60 of about 1,679 (144)
International Journal of Dermatology, Volume 65, Issue 2, Page 299-306, February 2026.ABSTRACT Background Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real‐world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.
Luca Potestio +50 more
wiley +1 more source
Allergy, Volume 81, Issue 1, Page 232-247, January 2026.The aim of the study is to interrogate immunological mechanisms induced by PQ Grass conventional and extended regimens. A short‐course pre‐seasonal subcutaneous injection of PQ Grass is effective in inducing immune tolerance by generating functional blocking antibodies and modulating T cell compartments.
Janice A. Layhadi +18 more
wiley +1 more source
Advances in Public Health, Volume 2026, Issue 1, 2026.Objective To assess the awareness and knowledge of ocular allergies (OAs) among undergraduate students in Trinidad and Tobago. Methods A cross‐sectional descriptive survey was conducted from December 2024 to March 2025 among full‐time undergraduate students at the University of the West Indies (UWI), St Augustine, Trinidad and Tobago.
Michael Agyemang Kwarteng +7 more
wiley +1 more source
Journal of Food Biochemistry, Volume 2026, Issue 1, 2026.Centaurea virgata is broadly used as a traditional food and medicine across the globe for numerous health purposes. Although the species is reported to have antioxidant and anti‐inflammatory activities, literature data on its gastroprotective effects are scarce.
Khalid M. Alqaisi +12 more
wiley +1 more source
Practice parameters for sublingual immunotherapy
Monaldi Archives for Chest Disease, 2016 The efficacy and safety of sublingual immunotherapy (SLIT) are currently supported by clinical trials, metaanalysis and post-marketing surveys. Practice parameters for clinical use of SLIT are proposed here by a panel of Italian specialists, with ...
C. Ortolani +39 more
doaj +1 more source
Allergy, Volume 80, Issue 12, Page 3391-3400, December 2025.SCIT at 50,000 AUeq/mL is safe and demonstrates clinically meaningful efficacy in patients with moderate to severe HDM‐induced allergic rhino‐conjunctivitis. Clinically relevant efficacy was observed in the moderate to severe group, but not in the overall study population, likely due to the inclusion of many patients with only mild symptoms. Safety and
Claus Bachert +11 more
wiley +1 more source
Updates in the treatment of ocular allergies
Journal of Asthma and Allergy, 2010 Osmo Kari1, K Matti Saari21Department of Allergology, Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland; 2Department of Ophthalmology, University of Turku, Turku, FinlandAbstract: Allergic diseases have greatly increased ...
Osmo Kari, K Matti Saari
doaj
Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study
Clinical Ophthalmology, 2023 Piotr Kuna,1 Marek Jutel,2,3 Grazyna Pulka,4 Slawomir Tokarski,5 Paula Arranz,6 Gonzalo Hernández,6 Nieves Fernández Hernando6 1Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland; 2Department of Clinical ...
Kuna P +6 more
doaj
Clinical and Translational Allergy, Volume 15, Issue 11, November 2025.ABSTRACT Background Atopic dermatitis (AD) often coexists with other type 2 inflammatory diseases. Stapokibart, a humanized IgG4 monoclonal antibody targeting interleukin‐4 receptor alpha subunit, showed high efficacy and favorable safety in a phase 3 trial.
Yan Zhao +26 more
wiley +1 more source
Allergology InternationalBackground: Artificial intelligence (AI) is a promising new technology that has the potential of diagnosing allergic conjunctival diseases (ACDs). However, its development is slowed by the absence of a tailored image database and explainable AI models ...
Michiko Yonehara +22 more
doaj +1 more source